MedTrace Logo

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

NCT04882956 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-05-12

No results posted yet for this study

Summary

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Conditions

  • Macula Lutea Degeneration

Interventions

DRUG

intravitreal injection

Brolucizumab-Dbll intravitreal injection

DRUG

intravitreal injection

Aflipercept intravitreal injection

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Tarek Elhamaky, MD · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-05
Primary Completion
2021-12-31
Completion
2022-03-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04882956 on ClinicalTrials.gov